Manganese for Blood Sugar and Glucose Metabolism

Rhodochrosite, a pink manganese mineral
Rhodochrosite, a pink manganese mineral

Manganese sits at the metabolic crossroads of glucose homeostasis. Two of the body's most important gluconeogenic enzymes — pyruvate carboxylase (the first committed step of gluconeogenesis) and phosphoenolpyruvate carboxykinase (PEPCK) — are manganese-dependent. Experimental manganese deficiency in rodents produces measurable abnormalities in glucose tolerance and insulin response. A Chinese case-control study found a U-shaped association between blood plasma manganese and type 2 diabetes — both low and high plasma levels went with higher odds — while studies of manganese in the diet found that people eating more manganese developed type 2 diabetes less often. Manganese also interacts with magnesium in glucose homeostasis: both minerals share transport routes, both are required for adenosine triphosphate-magnesium complex function in glucose phosphorylation, and combined deficiency produces synergistic dysregulation. While manganese is not a treatment for diabetes, adequate manganese status is one of the foundational nutritional requirements for normal glucose metabolism.


Table of Contents

  1. Why Glucose Metabolism Needs Manganese
  2. Pyruvate Carboxylase: The Gluconeogenic Entry Point
  3. Phosphoenolpyruvate Carboxykinase (PEPCK)
  4. TCA Cycle Anaplerosis and Glucose-Alanine Cycling
  5. Manganese Deficiency and Impaired Insulin Response
  6. Glucose Tolerance: Human Studies and Animal Models
  7. The Manganese-Magnesium Interplay in Glucose Homeostasis
  8. Type 2 Diabetes: U-Shaped Risk Curve
  9. MnSOD and Diabetic Complications
  10. Key Facts for People with Blood-Sugar Problems
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Why Glucose Metabolism Needs Manganese

Glucose homeostasis is the body's most carefully regulated metabolic parameter. Plasma glucose must be maintained within a narrow range (approximately 70-110 mg/dL in the fasting state) because both hypoglycemia (impaired brain function) and hyperglycemia (vascular and tissue damage) are immediately dangerous. The regulatory system has three principal components: dietary glucose absorption, hepatic glucose production (gluconeogenesis and glycogenolysis), and peripheral glucose uptake (especially by muscle and adipose tissue under insulin control).

Manganese is critical at two specific points in this system:

  1. Hepatic glucose production via gluconeogenesis — the synthesis of new glucose from non-carbohydrate precursors (lactate, amino acids, glycerol) during fasting, prolonged exercise, or low-carbohydrate states. Two of the four uniquely gluconeogenic enzymes — pyruvate carboxylase and PEPCK — require manganese.
  2. TCA cycle anaplerosis — replenishment of TCA cycle intermediates that are drawn off for biosynthesis. Pyruvate carboxylase is the principal anaplerotic enzyme, generating oxaloacetate from pyruvate.

The integration of these two roles places manganese directly in the path of glucose-handling in fasting metabolism. Inadequate manganese status compromises both gluconeogenesis (impaired generation of new glucose when needed) and TCA cycle function (impaired oxidative adenosine triphosphate (ATP) production from carbohydrate, fat, and protein substrates).

Back to Table of Contents

Pyruvate Carboxylase: The Gluconeogenic Entry Point

Pyruvate carboxylase (PC, EC 6.4.1.1) catalyzes the adenosine triphosphate-dependent carboxylation of pyruvate to oxaloacetate:

Pyruvate + CO2 + adenosine triphosphate → Oxaloacetate + ADP + Pi

This is the first committed step of gluconeogenesis from pyruvate or lactate, and it is also the principal anaplerotic reaction that replenishes oxaloacetate for TCA cycle function. The enzyme is a biotin-dependent carboxylase with a complex active-site architecture that includes both a biotin cofactor and a manganese ion (or, in some species and tissues, magnesium — the two divalent metals can substitute to some extent, but manganese has higher catalytic efficiency).

Back to Table of Contents

Phosphoenolpyruvate Carboxykinase (PEPCK)

PEPCK (EC 4.1.1.32) is the second committed enzyme of gluconeogenesis. It catalyzes the GTP-dependent decarboxylation and phosphorylation of oxaloacetate to phosphoenolpyruvate (PEP):

Oxaloacetate + GTP → PEP + CO2 + GDP

This reaction effectively reverses the pyruvate kinase step of glycolysis (which generates pyruvate from PEP). The combined PC + PEPCK pathway converts pyruvate to PEP, bypassing the irreversible pyruvate kinase reaction and committing carbon to the gluconeogenic direction.

Back to Table of Contents

TCA Cycle Anaplerosis and Glucose-Alanine Cycling

The tricarboxylic acid (TCA) cycle generates reduced nicotinamide adenine dinucleotide (NADH) and FADH2 for the electron transport chain and supplies precursors for biosynthesis: alpha-ketoglutarate for amino acid synthesis, succinyl-CoA for heme synthesis, oxaloacetate for gluconeogenesis and aspartate synthesis. When TCA intermediates are drawn off for biosynthesis (cataplerosis), they must be replaced (anaplerosis) or the cycle will run down.

Pyruvate carboxylase is the dominant anaplerotic enzyme in most mammalian tissues. Inadequate manganese reduces PC activity, slows anaplerosis, and gradually depletes TCA cycle intermediates. The result is reduced oxidative adenosine triphosphate production from all substrates (glucose, fatty acids, amino acids) and increased reliance on glycolytic (anaerobic) adenosine triphosphate production with lactate accumulation. This metabolic shift mimics in miniature what happens in more severe mitochondrial disorders.

The glucose-alanine cycle is one specific case where manganese's role is particularly visible. Working muscle generates alanine (from pyruvate by transamination with glutamate), which is exported to the liver. In the liver, alanine is converted back to pyruvate (with the amino group destined for the urea cycle, which itself requires manganese-containing arginase). Pyruvate then enters gluconeogenesis via manganese-dependent PC and PEPCK to regenerate glucose, which returns to the muscle. Manganese is required at two steps of this cycle (arginase in urea synthesis, PC and PEPCK in gluconeogenesis) plus one nitrogen-disposal step (glutamine synthetase in skeletal muscle for ammonia handling).

Back to Table of Contents

Manganese Deficiency and Impaired Insulin Response

Classical experimental manganese deficiency studies (rodents, guinea pigs) report that manganese deprivation impairs glucose handling and the insulin response. The one controlled human depletion study reports no glucose result in its published summary:

Back to Table of Contents

Glucose Tolerance: Human Studies and Animal Models

The human glucose-tolerance literature on manganese is limited and mixed:

Back to Table of Contents

The Manganese-Magnesium Interplay in Glucose Homeostasis

Magnesium and manganese have overlapping roles in glucose metabolism, and their statuses are nutritionally interrelated. Understanding the interplay helps clarify why neither mineral acts in isolation.

For more on magnesium and glucose metabolism, see the Magnesium page.

Back to Table of Contents

Type 2 Diabetes: U-Shaped Risk Curve

One of the more interesting findings in nutritional epidemiology of manganese is the U-shaped relationship between blood manganese and type 2 diabetes reported by Shan et al. (2016). In a Chinese case-control study of 3,228 people (1,614 with newly diagnosed type 2 diabetes and 1,614 without), the odds of diabetes were higher at both low and high plasma manganese — odds ratio 1.89 for the lowest third and 1.56 for the highest third, compared with the middle third — with the lowest odds at a plasma manganese of about 4.95 µg/L. Studies of manganese in the diet have found a falling, not U-shaped, risk (see below). Proposed reasons why both very low and very high manganese could matter:

A 2026 study pooled six long-term cohorts with more than 270,000 people: each extra 1 mg of manganese a day from food went with about 4% lower risk of type 2 diabetes (pooled relative risk 0.96, 95% CI 0.94-0.99), in a curved rather than straight-line pattern. In its own UK Biobank part (165,194 people), the highest-intake fifth did not have a significantly lower risk than the lowest fifth (hazard ratio 0.91, 95% CI 0.82-1.01), and heart and blood-vessel disease risk was unchanged (hazard ratio 0.99) (Gebretsadik et al., 2026).

None of these studies tested high-dose manganese supplements. A varied diet with whole grains, nuts, legumes, leafy greens, and tea typically supplies the Adequate Intake without supplements.

The U-shape also has an environmental-exposure component — populations with high environmental manganese (well water above EPA limits, certain industrial regions) may have elevated diabetes risk that masquerades as a "high-intake" effect but is really an inhalational or non-physiologic exposure problem.

Back to Table of Contents

MnSOD and Diabetic Complications

Once type 2 diabetes is established, mitochondrial superoxide overproduction in target tissues (vascular endothelium, retinal capillaries, renal tubular cells, peripheral nerves) is the upstream driver of the major chronic complications. The Brownlee unifying hypothesis places mitochondrial superoxide at the apex of the complication cascade:

  1. Hyperglycemia accelerates flux through the electron transport chain in target tissues
  2. Excess electron flow generates excess superoxide at complexes I and III
  3. If MnSOD capacity is exceeded, superoxide accumulates
  4. Superoxide activates four damaging downstream pathways (polyol, hexosamine, PKC, advanced glycation end-product formation)
  5. The four pathways converge on vascular and neuronal damage manifesting as nephropathy, retinopathy, neuropathy, and accelerated atherosclerosis

MnSOD adequacy is therefore upstream of the entire complication cascade. The SOD2 Val16Ala polymorphism (discussed in detail on the antioxidant MnSOD deep-dive) modulates this. In lab studies, the Val form of the enzyme gets into the mitochondria less well: the Ala form produced 30-40% more of the active enzyme than the Val form (Sutton et al., 2003). In a Danish study of people with type 1 diabetes (441 with diabetic kidney disease and 314 without it after at least 20 years of diabetes), carriers of the Val allele (Val/Val or Val/Ala) had more diabetic kidney disease (odds ratio 1.7, 95% CI 1.2-2.4) and more cardiovascular disease during follow-up (hazard ratio 1.6, 95% CI 1.0-2.5), independent of HbA1c (Möllsten et al., 2009).

This does not mean manganese supplementation prevents diabetic complications — the evidence does not support that claim. It means manganese adequacy is one of multiple inputs to a system that, when working well, buffers the diabetic state and slows complication onset.

Back to Table of Contents

Key Facts for People with Blood-Sugar Problems

This content is provided for informational purposes only and does not constitute medical advice. Nutrition is one component of diabetes care, alongside medicines, physical activity and blood-sugar monitoring.

Back to Table of Contents

Key Research Papers

  1. Friedman BJ, Freeland-Graves JH, Bales CW, et al. (1987). Manganese balance and clinical observations in young men fed a manganese-deficient diet. Journal of Nutrition 117(1):133-143. — PubMed PMID: 3819860
  2. Brownlee M (2005). The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54(6):1615-1625. — PubMed PMID: 15919781
  3. Koh ES, Kim SJ, Yoon HE, et al. (2014). Association of blood manganese level with diabetes and renal dysfunction: a cross-sectional study of the Korean general population. BMC Endocrine Disorders 14:24. — PubMed PMID: 24606630
  4. Du S, Wu X, Han T, et al. (2018). Dietary manganese and type 2 diabetes mellitus: two prospective cohort studies in China. Diabetologia 61(9):1985-1995. — PubMed PMID: 29971528
  5. Shan Z, Chen S, Sun T, et al. (2016). U-shaped association between plasma manganese levels and type 2 diabetes. Environmental Health Perspectives 124(12):1876-1881. — PubMed PMID: 27258818
  6. Gebretsadik GG, Yang B, Glenn AJ, et al. (2026). Dietary manganese, type 2 diabetes, and cardiovascular disease: a UK Biobank cohort study and meta-analysis of over 270,000 individuals. Journal of Nutrition, Health and Aging 30(2):100754. — PubMed PMID: 41380425
  7. Jomova K, Valko M (2011). Advances in metal-induced oxidative stress and human disease. Toxicology 283(2-3):65-87. — PubMed PMID: 21414382
  8. Burch HB et al. (1975). Hereditary pyruvate carboxylase deficiency: leigh-like syndrome and metabolic acidosis. Journal of Pediatrics. — PubMed
  9. Sutton A, Khoury H, Prip-Buus C, et al. (2003). The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13(3):145-157. — PubMed PMID: 12618592
  10. Möllsten A, Jorsal A, Lajer M, Vionnet N, Tarnow L (2009). The V16A polymorphism in SOD2 is associated with increased risk of diabetic nephropathy and cardiovascular disease in type 1 diabetes. Diabetologia 52(12):2590-2593. — PubMed PMID: 19834686
  11. Walter RM et al. (1991). Copper, zinc, manganese, and magnesium status and complications of diabetes mellitus. Diabetes Care 14(11):1050-1056. — PubMed PMID: 1797486
  12. Burrage LC et al. (2014). Disorders of branched chain amino acid metabolism: from rare leucine, isoleucine, and valine cycles to MSUD treatment paradigms. Human Molecular Genetics. — PubMed
  13. Rorsman P, Ashcroft FM (2018). Pancreatic beta-cell electrical activity and insulin secretion: of mice and men. Physiological Reviews 98(1):117-214. — PubMed PMID: 29212789

PubMed Topic Searches

  1. PubMed: Pyruvate carboxylase + manganese
  2. PubMed: PEPCK + manganese
  3. PubMed: Manganese + glucose tolerance
  4. PubMed: Manganese + T2DM epidemiology
  5. PubMed: Magnesium + manganese + glucose

Back to Table of Contents

Connections

Back to Table of Contents